WHAT'S NEW

HOME > WHAT'S NEW > Lumipulse® G PIVKA-II Launch in China

WHAT'S NEW

Lumipulse G PIVKA-II Launch in China

FUJIREBIO INC announced the launch of Lumipulse G PIVKA-II in China, a reagent for Fully Automated Chemiluminescent Enzyme Immunoassay System, LUMIPULSE® G1200.

Lumipulse G PIVKA-II will be the first PIVKA-II assay in China and will be distributed by ZHUHAI LIVZON DIAGNOSTICS.

Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) increase in patients with hepatocellular carcinoma (HCC) and is known as a specific tumor marker for HCC. The concentration of PIVKA-II in blood has no correlation with Alpha-fetoprotein (AFP), which is widely tested in China as a tumor marker for HCC.Consequently, AFP and PIVKA-II can be used as complementary markers for HCC.

Earlier diagnosis and the management of HCC is the key to the quality of life for HCC patients. PIVKA-II is useful for diagnosis of HCC, evaluation of medical treatments for HCC and diagnosis of recurrence of HCC in conjunction with diagnostic imaging method.

China has the biggest number of HCC patients world-wide. More than 70% of HCC patients are from Asian countries, over 300,000 patients from China, followed by Japan, Korea and Taiwan.

FUJIREBIO INC and ZHUHAI LIVZON DIAGNOSTICS INC are contributing to healthcare in China through the creation of new values with respect for human life and commitment to people’s health.

Contact : Naoaki Tamura (Global Sales Division)
Tel: +81-3-6279-0849
e-mail: fri-info@fujirebio.co.jp

PAGE TOP

Miraca Holdings
Fujirebio Inc. is a member of Miraca Group.